LAVAL, Quebec / Jun 21, 2023 / Business Wire / Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 20, 2023. The detailed results of the votes received by proxy are as follows:
Election of Directors
Director Nominees | NUMBER OF SHARES | PERCENTAGE OF VOTES CAST | ||
FOR | WITHHELD | FOR | WITHHELD | |
Daniel N. Chicoine | 4,113,511 | 91,743 | 97.8% | 2.2% |
Anthony E. Dobranowski | 3,549,815 | 655,439 | 84.4% | 15.6% |
John C. London | 3,550,494 | 654,760 | 84.4% | 15.6% |
Deborah Shannon-Trudeau | 4,115,644 | 89,610 | 97.9% | 2.1% |
Serge Verreault | 3,550,534 | 654,720 | 84.4% | 15.6% |
Appointment of External Auditors
Outcome | NUMBER OF SHARES | PERCENTAGE OF VOTES CAST | ||
FOR | WITHHELD | FOR | WITHHELD | |
Ernst & Young LLP reappointed | 4,965,906 | 47,466 | 99.1% | 0.9% |
Consideration of a Special Resolution Approving a Change of the Municipality of Crescita’s Registered Office
Outcome | NUMBER OF SHARES | PERCENTAGE OF VOTES CAST | ||
FOR | AGAINST | FOR | AGAINST | |
Change of municipality approved | 4,181,460 | 23,794 | 99.4% | 0.6% |
About Crescita Therapeutics Inc.
Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and early to commercial stage prescription products. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For further details, visit www.crescitatherapeutics.com.
| Last Trade: | C$0.48 |
| Daily Volume: | 8,500 |
| Market Cap: | C$9.060M |
November 05, 2025 August 06, 2025 May 23, 2025 March 18, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
